Content determination of obeticholic acid tablets by HPLC
Journal of Hebei University of Science and Technology, 2017 In order to establish a method for the content determination of obeticholic acid tablets, HPLC-UV method is adopted. The determination is performed on Agilent HC-C18 column（250 mm×4.6 mm,5 μm） with mobile phase acetonitrile (002% formic acid)-water (0 ...
Yunxia LU, Xingyan PAN, Jun YAO
doaj +1 more source
Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
Diseases, 2020 Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive destruction of the intrahepatic bile ducts. Currently, the first line drug for PBC is ursodeoxycholic acid (UDCA) characterized by anti-apoptotic ...
Ludovico Abenavoli +6 more
doaj +1 more source
Nonalcoholic steatohepatitis pharmacotherapy and predictors of response: dual role of aminotransferases as biosensors of metabolism and biomarkers of histological improvement [PDF]
, 2019 Nonalcoholic steatohepatitis (NASH)—the severe histological form of nonalcoholic fatty liver disease (NAFLD)—is regarded as a major health problem worldwide (1,2).
Pirola, Carlos José +1 more
core +1 more source
A Novel Telescoped Kilogram-Scale Process for Preparation of Obeticholic Acid
Pharmaceutical Fronts, 2021 A novel scalable four-step process has been developed to improve the synthesis of obeticholic acid (OCA). The key step of this process was the isolation of the amide intermediate, which underwent hydrogenation, basic epimerization, ketone reduction, and ...
Cheng-Wei Li +4 more
doaj +1 more source
Therapies for non-alcoholic steatohepatitis
Liver Research, 2017 Current phase 3 trials for the treatment of non-alcoholic steatohepatitis (NASH) are discussed in this review. Modalities that are based on weight loss include therapeutic lifestyle changes, pharmacological weight loss drugs (e.g., orlistat), and ...
Winston Dunn
doaj +1 more source
Repurposing drugs to target nonalcoholic steatohepatitis [PDF]
, 2019 Nonalcoholic fatty liver disease (NAFLD) is a complex disorder that has evolved in recent years as the leading global cause of chronic liver damage.
Pirola, Carlos José +1 more
core +1 more source
Obeticholic Acid Ameliorates Valproic Acid–Induced Hepatic Steatosis and Oxidative Stress [PDF]
Molecular Pharmacology, 2020 Farnesoid X receptor (FXR), or NR1H4, protects the liver from insults of various etiologies. A role of FXR in drug-induced liver injury has also been hypothesized yet only marginally investigated. The aim of this study was to assess the effect of FXR activation on gene expression and phenotype of the liver of mice treated with valproic acid (VPA), or 2-
Gai, Zhibo +4 more
openaire +2 more sources
Fibrates for Primary Biliary Cholangitis: What’s All the Hype?
Annals of Hepatology, 2017 Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was conditionally approved as a second-
Cynthia Levy
doaj +1 more source
Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-assigned Steatosis Grades of Liver Biopsies from Adults with Nonalcoholic Steatohepatitis [PDF]
, 2017 Background & Aims We assessed the diagnostic performance of magnetic resonance imaging (MRI) proton density fat fraction (PDFF) in grading hepatic steatosis and change in hepatic steatosis in adults with nonalcoholic steatohepatitis (NASH) in a multi ...
Bashir, Mustafa R. +15 more
core +1 more source